The PACER Lab at Purdue University is looking for volunteers age 18-30 years old for a study on PFASand brain activity (PI: Dr. Dan Foti, IRB protocol IRB-2023-1271).

This study aims to prospectively characterize venous congestion during early burn resuscitation by use of ultrasound and evaluate its relationship to traditional resuscitation metrics.THIS STUDY IS ENROLLING BY INVITATION ONLY - Potential subjects will be identified by the investigators by EMR review of burn ICU admissions. The investigators will meet with the patient inside their private hospital room and will discuss the study with the patient. All potential subjects that meet inclusion criteria and do not meet exclusion criteria will be approached for potential participation.

A cluster-randomized controlled trial (RCT) called "Reducing Risk of Dementia through Deprescribing" (R2D2) to evaluate the impact of a deprescribing intervention on important cognitive and safety outcomes.  This study will evaluate the effects of the use of a program to reduce prescribing of a group of commonly prescribed medications called anticholingerics that may adversely effect cognitive functioning in older adults. THIS STUDY IS ENROLLING BY INVITATION ONLY - ResNet data managers will identify physicians from the medical records of Community Health Network, and these participating physicians' patients will be approached for recruitment.' They may be contacted by phone or during clinic visits upon referral from physician.  Physicians agreeing to participate in the study will be randomized to intervention or usual care in random blocks of two or four and stratified by clinic site. Physician randomization status will determine participants’ study groups. Physicians randomized to usual care will not have access to the intervention. Physicians are not the subjects of the study. The subjects are the patients of the physicians. Physicians will not be aware of how or when their patients are being recruited or for what studies they will be offered.

This study is open to children aged 2 to 17 with chronic kidney disease (CKD). The purpose of this study is to find out if a medicine called empagliflozin helps children and adolescents with CKD. Other goals of the study are to find out how empagliflozin is tolerated and handled by the body in children and adolescents with CKD.THIS STUDY IS ENROLLING BY INVITATION ONLY

This is a phase 2, multicenter, randomized, placebo-controlled, double-blind, parallel-group, proof-of-concept study to assess vamifeport in adult participants with homeostatic iron regulator gene-related hereditary hemochromatosis (HFE-HH). The primary objective of the study is to assess the effect of vamifeport treatment on magnetic resonance imaging (MRI)-based liver iron concentration (LIC) in adult participants with HFE-HH.THIS STUDY IS ENROLLING BY INVITATION ONLY